Quantcast

Latest Philadelphia chromosome Stories

2014-06-02 12:28:29

High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed hematologists in China estimate that Novartis's Glivec (imatinib) will lose nearly half of its patient share for treatment of chronic myeloid leukemia (CML) in the next three years, due to the market entry of generic imatinib. Nevertheless,...

2014-05-23 16:23:48

FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate), now approved by the U.S. Food and Drug Administration for subcutaneous injection and home administration. SYNRIBO is a treatment for adults with chronic myeloid leukemia (CML) who are no longer responding to or are unable to tolerate two or more tyrosine kinase inhibitors (TKIs). The new...

2014-03-28 12:22:04

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/44vxfn/investigation ) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China...

2014-02-12 08:28:26

- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb. 12, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics. (Logo:...

2013-10-21 13:36:53

Study led by St. Jude Children's Research Hospital finds an inherited gene variation -- more common among Hispanic Americans -- is tied to increased risk of developing a high-risk form of pediatric leukemia Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome. The study appears today in the online...

2013-09-23 23:04:49

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022. London (PRWEB) September 23, 2013 PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia...

2013-09-18 23:04:35

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related